FLUCELVAX logo - influenza vaccine produced using cell-based technology

You put a lot of effort into protecting patients from the flu. With Flucelvax® you can provide an exact antigenic matched vaccine to the WHO-selected influenza strains.1-4†

† Does not predict a clinical effect
Illustration of a syringe labeled 'FLUCELVAX' piercing a green virus or bacteria, killing the flu virus
Green oval sign with white text reading '6mth+ for patients 6 months and over.'

DESIGNED TO BE AN EXACT MATCH TO WORLD HEALTH ORGANISATION (WHO) - SELECTED STRAINS 2,4-6 †

† Does not predict a clinical effect

Effectiveness

With data in people 6 months and older, you have an advanced option for flu vaccination this season.1

*Observational studies have limitations including potential for selection bias, residual confounding. Studies conducted in different seasons with different circulating strains. Studies carried out in either trivalent or quadrivalent formulation; effectiveness results are applicable to both. + Over 5 separate US seasons (2017-20, 2022-24) and across different datasets.

A colorful graphic with the text 'Up to 19.8% greater vaccine effectiveness from 5 US seasons compared to standard egg-based quadrivalent flu vaccine.'

Vaccine effectiveness of Flucelvax versus egg-based influenza vaccines7-18

WATCH HOW OUR CELL-BASED TECHNOLOGY WORKS19

ESTABLISHED SAFETY PROFILE1,20-24

In clinical trials, the most commonly reported adverse events were mostly mild or moderate in intensity.1,20-24 These include:

  • pain/redness at the injection site
  • headache
  • fatigue
  • irritability (Children 6 months - 3 years)
  • adverse events were tolerated with a safety profile similar to other flu vaccines
  • in 2 large randomised controlled trials conducted in children (N=2,332) and adults (N=2,680) there were no serious adverse events assessed as being related to study vaccines
  • Flucelvax is effective and well tolerated in pregnant women (Category A).1

†† Trivalent and quadrivalent doses
A circular graphic with a gradient from orange to green, displaying text about over 292 million doses distributed worldwide.

The importance of offering your patients a choice of influenza vaccine.

Brisbane GP, Dr Sarah Chu shares her experience on offering patients a choice of influenza vaccine and reflects on her clinical experience with Flucelvax®.

Summary

Infographic with two sections, one with a chart icon and text stating five years of validated evidence of Flucelvax's superior effectiveness over standard egg-based vaccines in individuals under 65, and the other with a virus icon and text about Flucelvax's safety and tolerance in adults, children, and pregnant women.
Illustration of a syringe labeled FLUCELVAX exploding a green virus particle.

Important information regarding ordering Flucelvax for 2026

Flucelvax will be available unfunded for the 2026 influenza season

Flucelvax can be ordered directly from HCL in the usual manner. Note: no minimum order quantity and no small order charge apply.

Flucelvax will cost $17.00+GST per dose from HCL, and will be available in boxes of 10 units.
Order Flu resources here

References: 1. Flucelvax Data sheet October 2024. 2. Centers for Disease Control and Prevention. Cell-based flu vaccines. Accessed Dec 2025. https://www.cdc.gov/flu/prevent/cell-based.htm 3. Rockman S et al. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 . 4. Rajaram S et al. Ther Adv Vaccines Immunother. 2020;8:2515135520908121. doi:10.1177/2515135520908121 5. Mabrouk T et al. Dev Biol (Basel). 2002;110:125–134. 6. WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season; Available from: https://cdn.who.int/ media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2022/ a(h3n2)---cell-culture-derived.pdf-cell_sh21.pdf?ua=1 Accessed Dec 2025. 7. Stein AN, et al. Open Forum Infect Dis. 2024;11(5):ofae175. 8. Stein A et al. Infect Dis Ther 3/10/2025; https://doi.org/10.1007/s40121-025-01230-2 9. Stein AN et al Influenza and Other Respiratory Viruses, 2025; 19:e70180 https://doi.org/10.1111/irv.70180 10. Krishnarajah G, et al. Vaccines (Basel). 2021;9(2):80. 11. Divino V, et al. Open Forum Infect Dis. 2021;9(1):ofab604. 12. Boikos C, et al. Clin Infect Dis.2020;71(10):e665-e671. 13. Boikos C, et al. Vaccines (Basel). 2022;10(6):896 13. Eick-Cost et al. International Conference on Emerging Diseases 2018. P109. 14. Bruxvoort KJ et al. Vaccine 37 (2019) 5807-5811. 15. DeMarcus L et al. Vaccine, 2019 (30): 4015-4021. 16. Martin ET et al. J Infect Dis, 2021; 223(12): 2062–2071. 17. Stein A et al. Presentation at ESWI Influenza Conference, 2023. 18. Tseng HF et al. Options X for the Control of Influenza 2019. Abstract 10395. 19. CSL Seqirus Data on File #11. 20. Bart S et al. Hum Vaccin Immunother. 2016;12(9):2278- 2288. 21. Hartvickson R et al. Int J Infect Dis. 2015;41:65-72. 22. FDA. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM504789.pdf. Accessed Dec 2024. 23. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04074928. Accessed Dec 2024. 24. Essink BJ et al. Pediatrics. 2022. 150(5):e2022057509. 25. Seqirus Data on File #9. 26. Nolan T et al. N Engl J Med. 2021; 385:16; 27. Albano M et al. IDSOG. Virtual Poster. 2021; V130_11OB

Flucelvax® is an unfunded Prescription Medicine. Flucelvax® is an inactivated trivalent influenza vaccine, prepared in cell cultures as a suspension for injection, in a single-dose glass syringe. PRESENTATION: Each dose of Flucelvax® Quad contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. Each dose of Flucelvax® contains 45 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from three influenza virus strains. INDICATIONS: For the prevention of influenza caused by Influenza Virus, types A and B, in adults and children 6 months of age and older. CONTRAINDICATIONS:  Known severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to any component of the vaccine. ADVERSE EVENTS: Local injection site pain, erythema and induration. Systemic headache, fatigue, myalgia, irritability, nausea, upper respiratory tract infection and nasopharyngitis. Post-marketing serious adverse events includes hypersensitivity reactions, anaphylactic shock; paraesthesia, Guillain-Barré syndrome; pruritus, urticaria, or non-specific rash; Extensive swelling of injected limb. PRECAUTIONS: Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients, particularly in immunosuppressed patients. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Flucelvax® Quad should be based on careful consideration of the potential benefits and risks. Treatment and supervision for anaphylactic reactions should be available. Co-administration with other vaccines has not been studied. DOSAGE AND ADMINISTRATION: By intramuscular injection only. Gently shake to produce a clear to slightly opalescent suspension before use. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the Flucelvax® Data Sheet (10/2024) www.medsafe.govt.nz, Seqirus Auckland, 0800 502 757. Flucelvax® is a registered trademark of Seqirus UK Ltd and its affiliates.

To report an adverse event to a CSL Seqirus product click here